A pilot randomized study on use of oral acetazolamide in patients with refractory dysuria

Hamidi, Morteza; Aghamir, Seyed Mohammad Kazem; Salavati, Alborz; Masoomi, Ahmad

doi:10.1007/s11255-017-1566-2

Cited by 2 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acetazolamide is also used to lower intracranial pressure or to increase the acidity of the blood by promoting bicarbonate excretion. 9 Choroidal effusion is considered an idiosyncratic reaction of the uveal tissue to acetazolamide, and the pathogenesis is mostly unknown.…”

Section: Discussionmentioning

confidence: 99%

Bilateral choroidal detachment and myopic shift after acetazolamide intake for laser capsulotomy

Musetti

Nicolò

Bagnis

et al. 2020

European Journal of Ophthalmology

View full text Add to dashboard Cite

Introduction: To report a case of bilateral choroidal effusion after laser capsulotomy. Case description: A healthy 85 years old white woman was referred to our hospital with a diagnosis of posterior capsule opacification in the left eye. The patient was treated with laser capsulotomy and oral acetazolamide was administered after the procedure. The day after, the patient visited the emergency room complaining bilateral blurred vision. A myopic shift and peripheral choroidal detachment was noted in both eyes. Discontinuation of acetazolamide and treatment with topical steroid and cyclopentolate resulted in a significant improvement in visual acuity and the complete resolution of the choroidal detachment in 1 week. Conclusion: To the best of our knowledge, this is the first reported case of choroidal detachment and acute transient myopia following the administration of oral acetazolamide after laser capsulotomy.

show abstract

Section: Discussionmentioning

confidence: 99%

Bilateral choroidal detachment and myopic shift after acetazolamide intake for laser capsulotomy

Musetti

Nicolò

Bagnis

et al. 2020

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence

et al. 2020

View full text Add to dashboard Cite

IntroductionAcetazolamide (AZM) is used for various conditions (eg, altitude sickness, sleep apnoea, glaucoma), but therapy is often limited by its side effect profile. Our objective was to estimate the risk of commonly reported side effects based on meta-analyses. We hypothesised that these risks are dose-dependent.MethodsWe queried MEDLINE/EMBASE (Medical Literature Analysis and Retrieval System Online/Excerpta Medica dataBASE) up until 04/10/2019, including any randomised placebo-controlled trial in which adults received oral AZM versus placebo reporting side effects. Eligibility assessment was performed by two independent reviewers. Data were abstracted by one reviewer who verified key entries at a second time point. For side effects reported by >3 studies a pooled effect estimate was calculated, and heterogeneity assessed via I2; for outcomes reported by >5 studies effect modification by total daily dose (EMbyTDD; <400 mg/d, 400–600 mg/d, >600 mg/d) was assessed via meta-regression. For pre-specified, primary outcomes (paraesthesias, taste disturbances, polyuria and fatigue) additional subgroup analyses were performed using demographics, intervention details, laboratory changes and risk of bias.ResultsWe included 42 studies in the meta-analyses (Nsubjects=1274/1211 in AZM/placebo groups). AZM increased the risk of all primary outcomes (p<0.01, I2 ≤16% and low-to-moderate quality of evidence for all)—the numbers needed to harm (95% CI; nStudies) for each were: paraesthesias 2.3 (95% CI 2 to 2.7; n=39), dysgeusia 18 (95% CI 10 to 38, n=22), polyuria 17 (95% CI 9 to 49; n=22), fatigue 11 (95% CI 6 to 24; n=14). The risk for paraesthesias (beta=1.8 (95% CI 1.1 to 2.9); PEMbyTDD=0.01) and dysgeusia (beta=3.1 (95% CI 1.2 to 8.2); PEMbyTDD=0.02) increased with higher AZM doses; the risk of fatigue also increased with higher dose but non-significantly (beta=2.6 (95% CI 0.7 to 9.4); PEMbyTDD=0.14).DiscussionThis comprehensive meta-analysis of low-to-moderate quality evidence defines risk of common AZM side effects and corroborates dose dependence of some side effects. These results may inform clinical decision making and support efforts to establish the lowest effective dose of AZM for various conditions.

show abstract

A pilot randomized study on use of oral acetazolamide in patients with refractory dysuria

Abstract: Oral acetazolamide can reduce the irritative voiding symptoms and improve the quality of life which is concomitant with an increase in urinary pH.

Cited by 2 publications

References 11 publications

Bilateral choroidal detachment and myopic shift after acetazolamide intake for laser capsulotomy

Bilateral choroidal detachment and myopic shift after acetazolamide intake for laser capsulotomy

Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence

Contact Info

Product

Resources

About